Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the 12 Best NASDAQ Penny Stocks to Buy According to Hedge Funds. On ...

Chris Gibson, PhD, Recursion’s co-founder and CEO, discusses exclusively with GEN Edge his company’s ambitious plans to develop 100 pipeline candidates in roughly a decade, the savings in money and ...

We believe that Recursion RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is likely to beat expectations when it reports second-quarter 2024 results. The ...

Machine-learning techniques keep improving efficiency in one industry after another. One corner of the economy where investors expect another big leap forward is the world of drug development. For ...

Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $4.77, signifying a -1.24% move from its prior day's close.

As a young and innovative company that heavily emphasizes the "tech" portion of the term "biotech," Recursion Pharmaceuticals (NASDAQ: RXRX) is a classic contender for being the kind of stock that can ...

Amidst the artificial intelligence (AI) revolution and a rapidly shifting landscape in drug development, Recursion Pharmaceuticals(NASDAQ: RXRX) is aiming to position itself at the intersection of ...

Everything touching artificial intelligence (AI) is hot right now, so it's no surprise that the biotech Recursion Pharmaceuticals (NASDAQ: RXRX) could be positioned to ride the ongoing wave of hype to ...

Companies whose breakthroughs revolutionize industries often end up being massively successful. Think Netflix's move from DVDs to streaming, or Apple's innovative smartphone that killed BlackBerry's ...